ARTHEx Biotech Announces Presentations at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) and Tides Europe 2023

USA - English

• España - español

VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19^th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain, and Tides Europe 2023, taking place October 30-November 1, 2023, in Amsterdam, NL. 

Details of the ARTHEx presentations during OTS are below:

Date/Time: Monday, October 23, 2023, 16.15–16.30
Session Title: Session III: Pre-Clinical II (Late Stage)
Oral Presentation Title: "Lipophilic conjugation ameliorates antimiR PK/PD properties"

ARTHEx's posters will be available for viewing during the Poster Sessions I and II, being held on October 24 and October 25, 2023.   Titles are listed below:

• "Systemic treatment with a lipophilic-conjugated antimir-23b rescues functional and molecular phenotypes of DM1 cognitive dysfunction in the DMSXL mice."
• "Enhanced muscle uptake of chemically optimized miR-23b antisense oligonucleotides as lead compounds for myotonic dystrophy."
• "Selection of relevant species for a nonclinical program of an antisense oligo."
• "Comprehensive assessment of potential hybridization-dependent off-target effects of ATX-01 including In Silico, In Vitro and In Vivo evaluation."
• "Advancing in vivo modeling and delivery systems for triplet repeat expansion-mediated corneal endothelial dystrophy: Implications in AntimiR therapy."
• "Effect of an antimiR on a knee OA rat model."

More information about the OTS meeting can be found here: link.

Details of the ARTHEx presentation during Tides Europe is below:

Date/Time: Wednesday, November 1, 2023, 08:55
Oral Presentation Title: "Use of a Lipophilic-conjugation to Deliver Antimir-23b into Skeletal Muscle and Nervous System for the Treatment of DM1"
Presenter: Beatriz Llamusi, PhD, Co-Founder and CSO of ARTHEx Biotech

More information about the Tides Europe meeting can be found here: link.

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs.  The Company's lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1.  The Company headquarters is in Valencia, Spain.

For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.

Company Contact

Frédéric Legros
Executive Chairman and CEO
[email protected]
+33679495790

Investor and Media Contact
Amy Conrad
Juniper Point
[email protected] 
+1 858-366-3243

SOURCE ARTHEx Biotech